Sandoz, Apotex And Taro Strike Civil Settlements On Price-Fixing
Further Settlements Worth A Total Of $447m Reached By Three Firms In US
Three civil settlements worth more than $447m in total have been reached with the US Department of Justice by Sandoz, Apotex and Sun’s Taro to resolve allegations over price-fixing. The deals follow criminal penalties previously paid by the three companies.
You may also be interested in...
In 2021, courts across the US and beyond continued to weigh key patent litigation fights, alongside the thorny issue of induced infringement via label carve outs and controversial charges for generic price fixing.
Sun Pharma’s US subsidiaries have agreed to pay out $85m to settle US antitrust litigation over generic price-fixing with direct purchaser plaintiffs.
In the latest development arising from ongoing generic pricing investigations in the US, Taro has admitted to fixing prices, allocating customers and rigging bids for generic medicines, under a conspiracy with multiple firms, including Sandoz.